[A22-07] Bimekizumab (plaque psoriasis) - Addendum to Commission A21-110
Last updated 03.03.2022
Project no.:
A22-07
Commission:
Commission awarded on 25.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adult patients with moderate to severe plaque psoriasis
Result of dossier assessment:
After addendum:
- Patients who are not candidates for conventional treatment in the framework of a first systemic therapy: hint of minor added benefit.
- Patients who have had an inadequate response or who have been intolerant to systemic therapy: proof of minor added benefit.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-110 | Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-03-03 A G-BA decision was published.